Previous 10 | Next 10 |
BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate i...
Notable additions during the quarter to Russell 2000 Index effective September 20, 2021 include: Krispy Kreme (NASDAQ:DNUT); Instructure (NYSE:INST); Verve Therapeutics (NASDAQ:VERV); Caribou Biosciences (NASDAQ:CRBU); Couchbase (NASDAQ:BASE); Weber (NYSE:WEBR); Flywire (NASDAQ:FLYW); Br...
Russell 3000 index adds IPO on a quarterly basis in addition to the annual reconstitution. Following tickers will be added to the index, effective Sept. 20: Figs (NYSE:FIGS), Krispy Kreme (NASDAQ:DNUT), Instructure Holdings (NYSE:INST), Verve Therapeutics (NASDAQ:VERV), Caribou Biosciences (N...
Shares of Caribou Biosciences Inc. (NASDAQ:CRBU) traded at a new 52-week high today of $32.61. This new high was reached on below average trading volume as 230,000 shares traded hands, while the average 30-day volume is approximately 903,000 shares. Caribou Biosciences Inc. (NASDAQ:CRBU)...
MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...
Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters’ option to purchase additional shares ANTLER Phase 1 clinical trial of CB-010 in relapsed or refractory B cell non-Hodgkin l...
Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc...
BERKELEY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a...
BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Nancy Whiting, Pharm.D., to its board of directors. Dr. Whiting brings over 17 years ...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today a...
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...